                         SEQUENCE LISTING

<110>  UTI Limited Partnership
 
<120>  TREATMENT OF FRAGILE X SYNDROME

<130>  PAT 88738W-90

<150>  US62/616,140
<151>  2018-01-11

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  313
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  fusion protein

<400>  1

Met Glu Glu Leu Val Val Glu Val Arg Gly Ser Asn Gly Ala Phe Tyr 
1               5                   10                  15      


Lys Ala Phe Val Lys Asp Val His Glu Asp Ser Ile Thr Val Ala Phe 
            20                  25                  30          


Glu Asn Asn Trp Gln Pro Asp Arg Gln Ile Pro Phe His Asp Val Arg 
        35                  40                  45              


Phe Pro Pro Pro Val Gly Tyr Asn Lys Asp Ile Asn Glu Ser Asp Glu 
    50                  55                  60                  


Val Glu Val Tyr Ser Arg Ala Asn Glu Lys Glu Pro Cys Cys Trp Trp 
65                  70                  75                  80  


Leu Ala Lys Val Arg Met Ile Lys Gly Glu Phe Tyr Val Ile Glu Tyr 
                85                  90                  95      


Ala Ala Cys Asp Ala Thr Tyr Asn Glu Ile Val Thr Ile Glu Arg Leu 
            100                 105                 110         


Arg Ser Val Asn Pro Asn Lys Pro Ala Thr Lys Asp Thr Phe His Lys 
        115                 120                 125             


Ile Lys Leu Asp Val Pro Glu Asp Leu Arg Gln Met Cys Ala Lys Glu 
    130                 135                 140                 


Ala Ala His Lys Asp Phe Lys Lys Ala Val Gly Ala Phe Ser Val Thr 
145                 150                 155                 160 


Tyr Asp Pro Glu Asn Tyr Gln Leu Val Ile Leu Ser Ile Asn Glu Val 
                165                 170                 175     


Thr Ser Lys Arg Ala His Met Leu Ile Asp Met His Phe Arg Ser Leu 
            180                 185                 190         


Arg Thr Lys Leu Ser Leu Ile Met Arg Asn Glu Glu Ala Ser Lys Gln 
        195                 200                 205             


Leu Glu Ser Ser Arg Gln Leu Ala Ser Arg Phe His Glu Gln Phe Ile 
    210                 215                 220                 


Val Arg Glu Asp Leu Met Gly Leu Ala Ile Gly Thr His Gly Ala Asn 
225                 230                 235                 240 


Ile Gln Gln Ala Arg Lys Val Pro Gly Val Thr Ala Ile Asp Leu Asp 
                245                 250                 255     


Glu Asp Thr Cys Thr Phe His Ile Tyr Gly Glu Asp Gln Asp Ala Val 
            260                 265                 270         


Lys Lys Ala Arg Ser Phe Leu Glu Phe Ala Glu Asp Val Ile Gln Val 
        275                 280                 285             


Pro Arg Asn Leu Val Gly Lys Val Ile Gly Ser Gly Gly Gly Tyr Gly 
    290                 295                 300                 


Arg Lys Lys Arg Arg Gln Arg Arg Arg 
305                 310             


<210>  2
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  tat polypeptide

<400>  2

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10      


<210>  3
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MGGSHHHHHHGMAS

<400>  3

Met Gly Gly Ser His His His His His His Gly Met Ala Ser 
1               5                   10                  


<210>  4
<211>  302
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  FMRP(289)

<400>  4

Met Glu Glu Leu Val Val Glu Val Arg Gly Ser Asn Gly Ala Phe Tyr 
1               5                   10                  15      


Lys Ala Phe Val Lys Asp Val His Glu Asp Ser Ile Thr Val Ala Phe 
            20                  25                  30          


Glu Asn Asn Trp Gln Pro Asp Arg Gln Ile Pro Phe His Asp Val Arg 
        35                  40                  45              


Phe Pro Pro Pro Val Gly Tyr Asn Lys Asp Ile Asn Glu Ser Asp Glu 
    50                  55                  60                  


Val Glu Val Tyr Ser Arg Ala Asn Glu Lys Glu Pro Cys Cys Trp Trp 
65                  70                  75                  80  


Leu Ala Lys Val Arg Met Ile Lys Gly Glu Phe Tyr Val Ile Glu Tyr 
                85                  90                  95      


Ala Ala Cys Asp Ala Thr Tyr Asn Glu Ile Val Thr Ile Glu Arg Leu 
            100                 105                 110         


Arg Ser Val Asn Pro Asn Lys Pro Ala Thr Lys Asp Thr Phe His Lys 
        115                 120                 125             


Ile Lys Leu Asp Val Pro Glu Asp Leu Arg Gln Met Cys Ala Lys Glu 
    130                 135                 140                 


Ala Ala His Lys Asp Phe Lys Lys Ala Val Gly Ala Phe Ser Val Thr 
145                 150                 155                 160 


Tyr Asp Pro Glu Asn Tyr Gln Leu Val Ile Leu Ser Ile Asn Glu Val 
                165                 170                 175     


Thr Ser Lys Arg Ala His Met Leu Ile Asp Met His Phe Arg Ser Leu 
            180                 185                 190         


Arg Thr Lys Leu Ser Leu Ile Met Arg Asn Glu Glu Ala Ser Lys Gln 
        195                 200                 205             


Leu Glu Ser Ser Arg Gln Leu Ala Ser Arg Phe His Glu Gln Phe Ile 
    210                 215                 220                 


Val Arg Glu Asp Leu Met Gly Leu Ala Ile Gly Thr His Gly Ala Asn 
225                 230                 235                 240 


Ile Gln Gln Ala Arg Lys Val Pro Gly Val Thr Ala Ile Asp Leu Asp 
                245                 250                 255     


Glu Asp Thr Cys Thr Phe His Ile Tyr Gly Glu Asp Gln Asp Ala Val 
            260                 265                 270         


Lys Lys Ala Arg Ser Phe Leu Glu Phe Ala Glu Asp Val Ile Gln Val 
        275                 280                 285             


Pro Arg Asn Leu Val Gly Lys Val Ile Gly Ser Gly Gly Gly 
    290                 295                 300         


